Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome
Conditions
Interventions
UX007
Placebo
Locations
14
United States
Children's Hospital Colorado - University of Colorado, Denver, School of Medicine
Aurora, Colorado, United States
Miami Children's Research Institute
Miami, Florida, United States
Neurology & Epilepsy Research Center
Orlando, Florida, United States
Columbia University - Department of Neurology
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Cook Children's Hospital
Fort Worth, Texas, United States
Start Date
February 28, 2014
Primary Completion Date
September 20, 2017
Completion Date
September 20, 2017
Last Updated
June 19, 2020
Lead Sponsor
Ultragenyx Pharmaceutical Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions